JP2010516688A - 抗菌ペプチド - Google Patents

抗菌ペプチド Download PDF

Info

Publication number
JP2010516688A
JP2010516688A JP2009546483A JP2009546483A JP2010516688A JP 2010516688 A JP2010516688 A JP 2010516688A JP 2009546483 A JP2009546483 A JP 2009546483A JP 2009546483 A JP2009546483 A JP 2009546483A JP 2010516688 A JP2010516688 A JP 2010516688A
Authority
JP
Japan
Prior art keywords
antimicrobial peptide
peptide
amino acids
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009546483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516688A5 (enExample
Inventor
ジエン フー
ランダル エイチ． エッケルト
フレンシア キ
マックスウェル エイチ． アンダーソン
ウェンユアン シ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2010516688A publication Critical patent/JP2010516688A/ja
Publication of JP2010516688A5 publication Critical patent/JP2010516688A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009546483A 2007-01-16 2008-01-15 抗菌ペプチド Pending JP2010516688A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88078307P 2007-01-16 2007-01-16
PCT/US2008/051101 WO2008140834A2 (en) 2007-01-16 2008-01-15 Novel antimicrobial peptides

Publications (2)

Publication Number Publication Date
JP2010516688A true JP2010516688A (ja) 2010-05-20
JP2010516688A5 JP2010516688A5 (enExample) 2013-05-23

Family

ID=40002852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009546483A Pending JP2010516688A (ja) 2007-01-16 2008-01-15 抗菌ペプチド

Country Status (8)

Country Link
US (2) US7713927B2 (enExample)
EP (1) EP2118122B1 (enExample)
JP (1) JP2010516688A (enExample)
CN (1) CN101622271B (enExample)
AU (1) AU2008251748B2 (enExample)
ES (1) ES2548767T3 (enExample)
IL (1) IL199835A (enExample)
WO (1) WO2008140834A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014218496A (ja) * 2013-04-08 2014-11-20 和興フィルタテクノロジー株式会社 高保存性抗体溶液
JP2017518976A (ja) * 2014-05-09 2017-07-13 ユニベルシテイト、ユトレヒト、ホールディング ベスローテン、フェンノートシャップＵｎｉｖｅｒｓｉｔｅｉｔ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 新しいｃａｔｈ２誘導体。
JP2023542830A (ja) * 2021-09-03 2023-10-12 深▲セン▼千越生物科技有限公司 抗菌ペプチド又はペプチド誘導体、置換体及びその組成物、製造方法及び応用

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
WO2008030988A2 (en) 2006-09-06 2008-03-13 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
WO2008140834A2 (en) * 2007-01-16 2008-11-20 The Regents Of The University Of California Novel antimicrobial peptides
EP2168976A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
US20100184684A1 (en) * 2009-01-06 2010-07-22 C3 Jian, Inc. Antibacterial and antifungal peptides
US20100202983A1 (en) * 2009-02-09 2010-08-12 Jernberg Gary R Selectively targeted antimicrobials for the treatment of periodontal disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10085938B2 (en) * 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US9987224B2 (en) * 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
WO2012154959A1 (en) * 2011-05-11 2012-11-15 Elixir Institute Of Regenerative Medicine Peptide tyrosinase inhibitors and uses thereof
US12083158B2 (en) * 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
US9028807B2 (en) 2012-04-05 2015-05-12 Ues, Inc. Synthesis models for antimicrobial agents via the halogenation of organic/inorganic composites
CN103172701B (zh) * 2013-03-18 2015-09-30 中国科学院过程工程研究所 一种新型穿膜肽及其应用
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
CN103830145B (zh) * 2014-03-18 2015-10-28 林彤 一种含有生物肽与中药的牙膏
US10131698B2 (en) * 2014-08-14 2018-11-20 Council Of Scientific & Industrial Research Synthetic antimicrobial peptides
CN106674329B (zh) * 2015-11-05 2021-07-23 程家维 具备抗微生物、抗癌/促进伤口愈合活性的肽及其用途
WO2017134661A1 (en) * 2016-02-04 2017-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
CN107337713B (zh) * 2016-05-03 2022-05-13 上海医药工业研究院 一组抑菌肽及其制备方法
CN106390206B (zh) * 2016-08-17 2019-06-28 广州宏柯源生物科技有限公司 一种多肽水凝胶、其制备方法及应用
KR101899552B1 (ko) * 2016-11-18 2018-09-17 군산대학교 산학협력단 전복에서 유래한 항균 펩타이드 유사체 및 이를 포함하는 항균용 약학 조성물
US10111929B1 (en) * 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
CN109232719B (zh) * 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants
US20220053773A1 (en) * 2018-10-01 2022-02-24 Innate Immunity LLC Compositions and methods for the treatment of pathogenic infections in plants
KR102170236B1 (ko) * 2019-03-19 2020-10-29 (주)노바셀테크놀로지 신규 다중 기능성 펩타이드 및 그의 용도
CN115244067A (zh) * 2019-08-29 2022-10-25 Ajk生物制药有限责任公司 合成抗微生物肽
EP4085064A4 (en) * 2019-12-30 2024-05-29 Ohio State Innovation Foundation LOOP PROTEINS INCLUDING CELL-PENETRATING PEPTIDES
EP4126906A1 (en) * 2020-03-31 2023-02-08 Innate Immunity LLC Recombinant peptide to treat fire blight
KR102220323B1 (ko) * 2020-05-15 2021-02-26 (주)노바셀테크놀로지 신규 다중 기능성 펩타이드 및 그의 용도
DE102020211387A1 (de) 2020-09-10 2022-03-10 Beiersdorf Aktiengesellschaft Wirkstoffhaltige Wundverschlusszubereitung
CN113248572B (zh) * 2021-04-30 2023-04-11 重庆理工大学 一种抗多重耐药菌环肽及其应用
US20230134577A1 (en) * 2021-09-20 2023-05-04 The Procter & Gamble Company Jammed Emulsion Toothpaste Compositions Comprising Fluoride
CN120289633B (zh) * 2025-02-27 2025-11-28 黄冈师范学院 抗变形链球菌的多肽、核酸分子及在制备抗变形链球菌的药物应用
CN120617172A (zh) * 2025-06-25 2025-09-12 中国科学院南海海洋研究所 一种安全无防腐剂的海龙抗菌肽喷雾剂及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118939A1 (en) * 1991-09-13 1993-04-01 W. Lee Maloy Biologically active amphiphilic peptide compositions and uses thereof
AUPN861496A0 (en) * 1996-03-13 1996-04-04 Commonwealth Scientific And Industrial Research Organisation Lytic peptides
CA2294518A1 (en) * 1997-07-15 1999-01-28 Magainin Pharmaceuticals Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
CA2320429C (en) * 1998-02-18 2011-04-19 Harbor-Ucla Research And Education Institute Antimicrobial peptides and derived metapeptides
US20040052814A1 (en) * 1998-09-28 2004-03-18 Wenyuan Shi Fusion proteins for targeted delivery of antimicrobial peptides
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US20020068066A1 (en) 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
US7569542B2 (en) * 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
AU2001287178A1 (en) * 2000-08-15 2002-02-25 North Carolina State University Antimicrobial peptides isolated from mast cells
US6449760B1 (en) * 2000-11-30 2002-09-10 Lsi Logic Corporation Pin placement method for integrated circuits
US6875744B2 (en) * 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
US7427408B2 (en) * 2002-06-06 2008-09-23 The Regents Of The University Of California Quorum sensing and biofilm formation
US7087228B2 (en) * 2002-07-03 2006-08-08 University Of Southern California Preventing tooth decay and infective endocarditis using natural oligopeptides
WO2004110341A2 (en) * 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
US7875598B2 (en) * 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
US7452856B2 (en) * 2004-07-06 2008-11-18 Seikagaku Corporation Antibacterial peptide
CA2581883A1 (en) * 2004-09-27 2006-04-06 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
CA2597191C (en) * 2005-02-09 2014-04-01 Helix Biomedix Inc. Antimicrobial hexapeptides
DK1869459T3 (da) * 2005-04-05 2010-09-27 Allergan Inc Lipofil farve-baserede assays for clostridial-toksin-aktivitet
WO2007005635A2 (en) * 2005-07-01 2007-01-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor
CA2620935A1 (en) 2005-09-01 2007-03-08 The Regents Of The University Of California Method of using pore-forming peptides for genetic transformation, protein extraction, and transmembrane transport
EP1957094B1 (en) * 2005-09-28 2015-09-16 The Regents of The University of California Calcium binding peptides
EP2061886B1 (en) * 2006-08-21 2014-05-07 The University Of British Columbia Small cationic immunomodulatory peptides
WO2008030988A2 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
WO2008140834A2 (en) 2007-01-16 2008-11-20 The Regents Of The University Of California Novel antimicrobial peptides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012049894; Ａｎｔｉｍｉｃｒｏｂ．Ａｇｅｎｔｓ　Ｃｈｅｍｏｔｈｅｒ．，Ｖｏｌ．５０，Ｎｏ．１１（２００６）ｐ．３６５１-３６５７ *
JPN6013022438; Ｏｒａｌ　Ｍｉｃｒｏｂｉｏｌ．Ｉｍｍｕｎｏｌ．，Ｖｏｌ．６（１９９１）ｐ．１６９-１７６ *
JPN6013022440; Ｂｉｏｃｈｅｍ．Ｊ．，Ｖｏｌ．３２６（１９９７）ｐ．３９-４５ *
JPN6013022443; Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，Ｖｏｌ．６５，Ｎｏ，７（１９９７）ｐ．２８９８-２９０３ *
JPN6013022447; ＦＥＢＳ　Ｊ．，Ｖｏｌ．２７４（２００７）ｐ．３７７-３８９（Ｐｕｂｌｉｓｈｅｄ　Ｏｎｌｉｎｅ　Ｄｅｃ．２００６） *
JPN6013022450; Ａｎｔｉｍｉｃｒｏｂ．Ａｇｅｎｔｓ　Ｃｈｅｍｏｔｈｅｒ．，Ｖｏｌ．５０，Ｎｏ．１０（２００６）ｐ．３３０５-３３１１ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014218496A (ja) * 2013-04-08 2014-11-20 和興フィルタテクノロジー株式会社 高保存性抗体溶液
JP2017518976A (ja) * 2014-05-09 2017-07-13 ユニベルシテイト、ユトレヒト、ホールディング ベスローテン、フェンノートシャップＵｎｉｖｅｒｓｉｔｅｉｔ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 新しいｃａｔｈ２誘導体。
JP2020109109A (ja) * 2014-05-09 2020-07-16 ユニベルシテイト、ユトレヒト、ホールディング ベスローテン、フェンノートシャップＵｎｉｖｅｒｓｉｔｅｉｔ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 新しいｃａｔｈ２誘導体。
US10829524B2 (en) 2014-05-09 2020-11-10 Universiteit Utrecht Holding B.V. CATH2 derivatives
US11603391B2 (en) 2014-05-09 2023-03-14 Universiteit Utrecht Holding B.V. CATH2 derivatives
JP2023542830A (ja) * 2021-09-03 2023-10-12 深▲セン▼千越生物科技有限公司 抗菌ペプチド又はペプチド誘導体、置換体及びその組成物、製造方法及び応用
JP7717797B2 (ja) 2021-09-03 2025-08-04 深▲セン▼千越生物科技有限公司 抗菌ペプチド又はペプチド誘導体、置換体及びその組成物、製造方法及び応用

Also Published As

Publication number Publication date
WO2008140834A2 (en) 2008-11-20
IL199835A0 (en) 2010-04-15
US20080286210A1 (en) 2008-11-20
US7713927B2 (en) 2010-05-11
AU2008251748A1 (en) 2008-11-20
EP2118122A2 (en) 2009-11-18
IL199835A (en) 2017-09-28
CN101622271B (zh) 2014-08-27
US8609608B2 (en) 2013-12-17
WO2008140834A3 (en) 2009-08-13
EP2118122A4 (en) 2012-12-12
CN101622271A (zh) 2010-01-06
ES2548767T3 (es) 2015-10-20
AU2008251748B2 (en) 2014-02-27
EP2118122B1 (en) 2015-09-23
US20110085989A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
JP2010516688A (ja) 抗菌ペプチド
US8303962B2 (en) Antibacterial and antifungal peptides
AU2002324752B2 (en) Antimicrobial cationic peptides and formulations thereof
JP5335241B2 (ja) 抗微生物ヘキサペプチド
WO2010091294A2 (en) New targeted antimicrobial moieties
JP2017526640A5 (enExample)
JP2017526640A (ja) Ｓ．ミュータンス（Ｓ．ｍｕｔａｎｓ）を結合させるターゲティングペプチド、そのようなペプチドを含む構築物、およびその使用
US20110262508A1 (en) Antimicrobial compositions, formulations and uses thereof
HK1205139A1 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9181303B2 (en) Treatment of bacterial infections with cyclic antimicrobial peptides
US20030219854A1 (en) Methods for producing modified anti-infective peptides
US7745390B2 (en) Antimicrobial peptides
JP2006045214A (ja) 抗菌性ペプチド
US20250275905A1 (en) Antibacterial and mineralizing compositions and methods of use thereof
JPH06504260A (ja) 両親媒性ペプチド組成物及びその類似体
WO2002102835A2 (en) Novel antimicrobial compounds
CN101389642B (zh) 环状抗微生物肽
JP4817335B2 (ja) 新規抗菌性ペプチド
US20200071357A1 (en) Antimicrobial peptides
JP3232675B2 (ja) 新規ペプチドおよび抗菌剤
HK1136211B (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140404